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Pyrimidine salts such as 2-methyl-5-nitro-phenyl-(4-pyridin-3-yl-pyrimidin-2-yl)-amine (1) and 4-methyl-3-(4-pyridin-3-yl-
pyrimidin-2-yl-amino)-phenyl-amine (2) with chloranilic and picric acids were synthesized, and their in vitro antibacterial and
antifungal activities were evaluated. e synthesized compounds were characterized by elemental analyses, UV-visible, FT-IR,
and 1H NMR spectral studies. Compound 2a exhibited good inhibition towards antimicrobial activity compared to the other
compounds.
1. Introduction
e health problem demands to search and synthesize a new
class of antimicrobial compounds which are eﬀective against
pathogenic microorganisms and develop resistance to the
antibiotics used in the current regime [1]. e increasing
resistance of human pathogens to current antimicrobial
agents is a serious medical problem. During the 20th century,
vaccines for bacterial toxins and many other common acute
viral infections were developed and made widely available.
e incidence of fungal infections has increased signi�cantly
in the past two decades [2]. e �rst-generation antifungal
inhibitors of CYP51 have revolutionized the treatment of
some serious fungal infections.
e pyrimidine derivatives possess a wide variety of
potentially biological properties and are well known to work
as herbicides [3, 4] and pesticides [5]. Pyrimidine derivatives
have been found to exhibit cytostatic [6–9] immunomodulat-
ing [10, 11] and antimicrobial properties [12–15]. Imatinib
is a new anticancer agent, and it is currently marketed by
as Gleevec. It is a protein tyrosine kinase inhibitor that
inhibits the Bcr-Abl tyrosine kinase, the constitutive abnor-
mal tyrosine kinase created by the Philadelphia chromosome
abnormality in chronic myeloid leukemia (CML) [16]. It
has also been found to be eﬀective in the treatment of
gastrointestinal stromal tumors (GISTs) [17]. is selective
inhibition of Bcr-Abl kinase by imatinib has been a successful
therapeutic strategy for CML because of the high eﬃcacy
and mild side eﬀects of this compound [18, 19]. Chloranilic
acid (CA) and picric acid (PA) form salts with many organic
compounds particularly with aromatic and aliphatic amines.
In connectionwith such studies, the present paper reports
the salts formed by the reaction of 2-methyl-5-nitro-phenyl-
(4-pyridin-3-yl-pyrimidin-2-yl)-amine (1) and 4-methyl-
3-(4-pyridin-3-yl-pyrimidin-2-yl-amino)-phenyl-amine (2)
with chloranilic and picric acids. ese synthesized com-
pounds were characterized by diﬀerent spectral studies and
biological results were reported in this paper. On the basis
of their activity, these salts were identi�ed as viable leads for
further studies.
2. Experimental
All solvents and reagents were purchased from Sigma-
Aldrich, India. Melting points were determined by Veego
Melting Point VMP-III apparatus. Elemental analysis was
carried out on Perkin Elmer 2400 elemental analyser. e
UV-visible spectra were recorded on Analytikjena Specord
50 UV-vis spectrophotometer with quartz cell of 1.0 cm path
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length in DMSO. e infrared spectra on KBr pellets in the
range of 4000–400 cm−1 were recorded on Jasco FT-IR 4100
series. FT-IR spectrophotometer provided with KBr optics.
e NMR spectra were recorded using Bruker DRX 400
spectrometer at 400MHz for 1HNMRwith tetramethylsilane
as the internal standard. Compounds 1a-b and 2a-b were
synthesized by the method summarized in Scheme 1.
2.1. General Procedure for the Synthesis of 1a and 2a. e
reaction between imatinib intermediates (1.0 eq) with chlo-
ranilic acid (1.0 eq) in ethanol (10mL). e reaction mixture
was stirred at room temperature for 2 h, where the solid
precipitated aer the reduction of the volume of the solvent.
e separated precipitate was �ltered oﬀ, washed several




dienolate (1a). e general synthetic method described
above aﬀorded 1a, and the product obtained was violet-
colored solid from 2-methyl-5-nitro-phenyl-(4-pyridin-3-
yl-pyrimidin-2-yl)-amine, 1 (0.31 g, 1mmol) and chloranilic
acid (CA) (0.22 g, 1mmol). 1H NMR (DMSO-d6, 400MHz)
𝛿𝛿: 9.35 (s, 1H, pyridine-H), 9.30 (d, 1H, pyridine-H), 8.90 (s,
1H, N–H), 8.77 (s, 1H, Ar–H), 8.75 (d, 1H, pyrimidine-H),
8.63 (s, 2H, NH2), 7.90 (d, 1H, pyridine-H), 7.88 (d, 1H,
Ar–H), 7.69 (t, 1H, pyridine-H), 7.59 (d, 1H, Ar–H), 7.49 (d,
1H, pyrimidine-H), 2.40 (s, 3H, CH3). FT-IR (KBr, cm−1)
𝜈𝜈: 3328 (N–H), 3108 (Ar–H), 1672 (C=O), 1578 (C=C),
1379 (C–C), 1287 (C–O), 1108 (C–N), 839 (C–Cl). Anal.
Calcd. For C22H15Cl2N5O6 (in%): C-51.18, H-2.93, N-13.56.
Found C-50.91, H-3.27, N-13.46%.
2.3. 4-Methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phe-
nyl-ammonium-2,5-dichloro-4-hydroxy-3,6-dioxo-cyclohexa-
1,4-dienolate (2a). e general synthetic method described
above aﬀorded 2a, and the product obtained was violet-
colored solid from 4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-
ylamino)-phenyl-amine, 2 (0.28 g, 1mmol) and chloranilic
acid (CA) (0.22 g, 1mmol). 1H NMR (DMSO-d6, 400MHz)
𝛿𝛿: 8.96 (s, 1H, N–H), 8.81 (s, 3H, NH3), 8.70 (s, 1H, pyridine-
H), 8.51 (s, 1H, Ar–H), 8.43 (d, 1H, pyridine-H), 8.41 (d,
1H, pyrimidine-H), 7.55 (d, 1H, pyridine-H), 7.51 (t, 1H,
pyridine-H), 7.46 (d, 1H, Ar–H), 7.22 (d, 1H, Ar–H), 6.84
(d, 1H, pyrimidine-H), 2.21 (s, 3H, CH3). FT-IR (KBr, cm−1)
𝜈𝜈: 3400 (
+
NH3), 3163 (N–H), 3066 (Ar–H), 1505 (C=O), 1445
(C=C), 1203 (C–C), 1129 (C–O), 1040 (C–N), 869 (C–Cl).
Anal. Calcd. For C22H17Cl2N5O4 (in %): C-54.34, H-3.52,
N-14.40. Found C-53.96, H-3.20, N-14.13%.
2.4. General Procedure for the Synthesis of 1b and 2b. e
reaction between imatinib and its intermediates (1.0 eq) with
picric acid (1.0 eq) in ethanol (10mL). e reaction mixture
was stirred at room temperature for 1 h, where the solid
precipitated aer the reduction of the volume of the solvent.
e separated precipitate was �ltered oﬀ, washed several
times with diethyl ether (2 × 0.5mL), and dried in vacuum
over CaCl2.e crude product was puri�ed by crystallization
from methanol solvent.
2.5. 2-Methyl-5-nitro-phenyl-(4-pyridin-3-yl-pyrimidin-2-yl)-
ammonium Picrate (1b). e general synthetic method
described above aﬀorded 1b, and the product obtained
was yellow colored solid from 2-methyl-5-nitro-phenyl-
(4-pyridin-3-yl-pyrimidin-2-yl)-amine, 1 (0.31 g, 1mmol)
and picric acid (PA) (0.23 g, 1mmol). 1H NMR (DMSO-
d6, 400MHz) 𝛿𝛿: 9.33 (s, 1H, pyridine-H), 9.28 (d, 1H,
pyridine-H), 8.82 (s, 1H, N–H), 8.73 (s, 1H, Ar–H), 8.65
(d, 1H, pyrimidine-H), 8.55 (s, 2H, C6H2of PA), 7.90 (d,
1H, pyridine-H), 7.88 (d, 1H, Ar–H), 7.78 (t, 1H, pyridine-
H), 7.61 (d, 1H, Ar–H), 7.49 (d, 1H, pyrimidine-H), 2.40 (s,
3H, CH3). FT-IR (KBr, cm−1) 𝜈𝜈: 3401 (N–H), 3093 (Ar–H),
1407 (NO2), 1346 (C–C), 1083 (C–N). Anal. Calcd. For
C22H16N8O9 (in %): C-49.26, H-3.01, N-20.89. Found C-
48.89, H-3.27, N-20.57%.
2.6. 4-Methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phe-
nyl-ammonium Picrate (2b). e general synthetic method
described above aﬀorded 2b, and the product obtained
was yellow-colored solid from 4-methyl-3-(4-pyridin-3-yl-
pyrimidin-2-ylamino)-phenyl-amine, 2 (0.28 g, 1mmol)
and picric acid (PA) (0.23 g, 1mmol). 1H NMR (DMSO-d6,
400MHz) 𝛿𝛿: 9.27 (s, 1H, pyridine-H), 9.26 (s, 1H, Ar–H),
9.03 (s, 1H, N–H), 8.90 (s, 3H, NH3), 8.71 (d, 1H, pyridine-
H), 8.55 (s, 2H, PA), 8.53 (d, 1H, pyrimidine-H), 8.46 (d,
1H, pyridine-H), 7.57 (t, 1H, pyridine-H), 7.48–7.30 (d, 2H,
Ar–H), 6.96 (d, 1H, pyrimidine-H), 2.25 (s, 3H, CH3). FT-IR
(KBr, cm−1) 𝜈𝜈: 3437 (
+
NH3), 3178 (N–H), 3068 (Ar–H),
1837 (C=C), 1360 (C–C), 1078 (C–N). Anal. Calcd. For
C22H18N8O7 (in %): C-52.18, H-3.58, and N-22.13. Found
C-51.95, H-3.93, N-22.46%.
2.7. Antibacterial Activity. Antibacterial activity of the syn-
thesized compounds was determined against Gram-positive
bacteria (Bacillus subtilis and Staphylococcus aureus) and
Gram-negative bacteria (Escherichia coli and Xanthomonas
malvacearum ) in DMF by disc diﬀusion method on nutri-
ent agar medium [20]. e sterile medium (nutrient agar
medium, 15mL) in each Petri plates was uniformly smeared
with cultures of Gram-positive and Gram-negative bacteria.
Sterile discs of 10mm diameter (Hi-Media) were made in
each of the Petri plates, to which 50 𝜇𝜇L (1mg/mL, that is,
50 𝜇𝜇g/disc) of the diﬀerent synthesized compounds were
added. e treatments also included 50𝜇𝜇L of DMF as nega-
tive, streptomycin (1mg/mL; 10 𝜇𝜇g/disc) as positive control
for comparison. For each treatment, three replicates were
maintained. e plates were incubated at 37 ± 2∘C for 24 h,
and the size of the resulting zone of inhibition, if any, was
determined.
2.8. Antifungal Activity. e synthesized compounds were
screened for their antifungal activity against Fusarium oxys-
porum in DMF by poisoned food technique [21]. Potato



































































S 1: e illustration of the synthesis of 1a-b and 2a-b.
dextrose agar (PDA) media were prepared, and about 15mL
of PDA was poured into each Petri plate and allowed to
solidify. 5mm disc of seven-day-old culture of the test fungi
was placed at the center of the Petri plates and incubated at
26∘C for 7 days. Aer incubation, the percentage inhibition
was measured and three replicates were maintained for each
treatment. Nystatin was used as standard. All the synthesized
compounds, and nystatin were tested (at the dosage of
500 𝜇𝜇L of the compounds/Petri plate, where concentration
was 0.1mg/mL) by poisoned food technique.
3. Results and Discussion
eelemental analyses data showed good agreement between
the experimentally determined values and the theoretically
calculated values within the limits of permissible error. New
bands were detected in the UV-visible spectra of the salts.
ese bands are not exhibited by either donor or acceptors
alone. e appearance of longer wavelength absorption band
in the visible region in UV-visible spectrum owing to the
charge transfer transition con�rms the formation of prod-
ucts. Yield, melting point, and UV-visible spectral data of the
synthesized salts are listed in Table 1.
e infrared spectra of the molecular salts of CA and
PA with donors indicate that 𝜈𝜈(C–Cl) of CA and 𝜈𝜈(NO2) of
PA are shied to lower wavenumber values. e stretching
T 1: Physical characterization of the synthesized compounds.
Compound Yield (%) M. P (∘C) UV-visible (𝜆𝜆max)
1a 60 218–220 530
1b 56 174–176 530
2a 61 198–202 420
2b 64 200–203 455
frequency of C=O bond of the acceptor displays a shi to a
higher wavenumber values. Infrared spectra of the synthe-
sized complexes show a strong band, indicating
+
N–H⋯O−
stretching vibration of the intermolecular hydrogen bond.
Compounds showed signals around 2.1–2.9 ppm and in
the region 6.8–9.4 ppm due to methyl group and aromatic
group of the synthesized salts. New signals are observed at
8.81–8.90 ppm assigned to
+
N–H proton. e O–H signals of
the free CA and free PA were disappeared on salt formation.
ese data is agreed quite well with the elemental analyses,
UV-visible and FT-IR studies.
3.1. Antibacterial Activity. e investigation of antibacterial
screening data revealed that synthesized salts was evalu-
ated and compared with standard drug streptomycin. Com-
pounds 1a, 1b, and 2b showed less inhibitory activity against
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T 2: In vitro antibacterial and antifungal activities of synthesized compounds.
Compounds Diameter of inhibition zone (mm) % inhibition
B. subtilis S. aureus X. malvacearum E. coli F. oxysporum
1a 11 12 13 13 43.0
1b 11 11 12 12 41.1
2a 13 15 16 14 56.4
2b 11 12 13 14 48.3
Streptomycin 18 20 18 19 —
Nystatin — — — — 85.2
Bacillus subtilis, Staphylococcus aureus, and Escherichia coli.
Compound 2a exhibited good activity with the zone of
inhibition in the range of 16mm against pathogenic bacterial
strain.
3.2. Antifungal Activity. e antifungal activity of synthe-
sized salts were evaluated and compared with standard
drug nystatin. All the synthesized salts showed moderate
inhibitory activity compared with standard drug. Compound
2a showed good antifungal activity with the 56.4% inhibition
against F. oxysporum, compared with 2b, 1a, and 1b. Among
the synthesized salts, inhibitory activity is in the order of
2a > 2b > 1a > 1b > against tested fungi. e compound
2a exhibited good activity against fungal strain. e salts
of imatinib and its intermediates with chloranilic acid are
more antimicrobial activity comparedwith salts of picric acid.
Antimicrobial screening results of the tested salts are shown
in Table 2.
4. Conclusion
In conclusion, salts of pyrimidines with chloranilic and
picric acids were synthesized in good yield, characterized by
diﬀerent spectral studies, and their antimicrobial activity has
been evaluated. Compound 2a demonstrated good inhibition
against all the strains tested. It should be noted that com-
pound 2a demonstrated better inhibition compared to other
compounds against bacterial and fungal strains tested.
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